News | April 27, 2022
Lasa Supergenerics bags Rs. 50 crore orders
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Floods had forced the plans in Mahad to shut down
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Valorum will advance the commercialization and distribution of Armlupeg in the United States
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Subscribe To Our Newsletter & Stay Updated
